DexCom Inc
Închisă
SectorSănătate
69.73 1.19
Rezumat
Modificarea prețului
24h
Minim
68.85
Maxim
71.01
Venit | -68M 200M |
|---|---|
Vânzări | -68M 1.2B |
P/E Medie Sector | 29.644 50.958 |
EPS | 0.56 |
Marjă de profit | 16.738 |
Angajați | 11,000 |
EBITDA | -52M 337M |
Recomandări | Puternic Cumpărare |
|---|---|
Prognoză pe 12 luni | +19.86% upside |
Următoarele câștiguri | 29 iul. 2026 |
|---|
Capitalizare de piață | 3B 27B |
|---|---|
Deschiderea anterioară | 68.54 |
Închiderea anterioară | 69.73 |
Sentimentul știrilor
By Acuity
18%
82%
35 / 342 Clasament în Healthcare
DexCom Inc Grafic
Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.
Despre DexCom Inc
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. It has also submitted FDA review for Dexcom Stelo for people with type 2 diabetes. The company has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. It markets its products directly to endocrinologists, physicians, and diabetes educators. The company was incorporated in 1999 and is headquartered in San Diego, California.